Press Releases

BETHESDA, Md., July 24, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer (the “Trial”) has been completed and all of the sites have signed off on the locking of their data. As noted... Read More

BETHESDA, Md., June 2, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer. The Company reported that the final data collection process has been progressing steadily despite ongoing difficulties due to coronavirus-related... Read More

BETHESDA, Md., April 18, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers, will discuss the projected schedule for reaching data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer at the Company’s 2019 Annual... Read More

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder’s Meeting will be held on April 18, 2020, at 1:00 pm in Washington, DC. Read More

For Immediate Release on Thursday, December 12, 2019 Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team Executive With Decades of Public and Private Company Experience Joins NW Bio As CFO BETHESDA, Md., December 12, 2019 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further... Read More